{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:24:57Z","timestamp":1792207497267,"version":"4.4.0"},"reference-count":60,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Reduced-intensity conditioning (RIC), haploidentical donors, and posttransplantation cyclophosphamide (PTCy) have overcome many barriers associated with bone marrow transplantation (BMT) for sickle cell disease (SCD). However, initial approaches had high graft failure rates. Our preliminary data suggested increasing the total body irradiation (TBI) dose from 200 to 400 cGy could improve engraftment. This study included patients with SCD aged 2 to 70 years undergoing BMT from November 2014 to January 2025. The regimen included antithymocyte globulin, fludarabine, cyclophosphamide, and single-fraction 400 cGy TBI. Graft-versus-host disease (GVHD) prophylaxis included PTCy, mycophenolate mofetil, and sirolimus. Outcomes measured were disease-free survival (DFS), graft failure, overall survival (OS), and GVHD incidence. A total of 43 patients (median age, 23 years) received a transplant; 34 (79%) had \u22652 indications for BMT, and all had \u22652 SCD comorbidities. Five-year OS probability was 95.5% (95% confidence interval [CI], 0.87-1.0) at a median follow-up of 2.43 years. DFS probability at 2 years was 94.5% (95% CI, 0.87-1.0), with only 2 (5%) graft failures. Two patients died late (2.5 and 6 years) after BMT. The cumulative incidence of grade 3\/4 acute GVHD was 2.4% (95% CI, 0-0.07), and that of moderate-severe chronic GVHD was 7.3% (95% CI, 0-0.15). Median time to discontinuation of immunosuppression was 354 days. Of 27 female patients, 12 had return of menses and\/or normalized gonadal function. RIC haploidentical BMT with 400 cGy maintained a low-toxicity profile, provides high rates of durable engraftment, and may preserve fertility. This regimen expands the availability of curative therapy for severe SCD. This trial was registered at www.ClinicalTrials.gov as NCT00489281.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017413","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T16:48:05Z","timestamp":1769100485000},"page":"2202-2217","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Bone marrow transplantation for sickle cell disease using posttransplantation cyclophosphamide and 400 cGy TBI"],"prefix":"10.1182","volume":"10","author":[{"given":"Marti","family":"Goldenberg","sequence":"first","affiliation":[{"name":"1Division of Pediatric Oncology\/Bone Marrow Transplantation, Bloomberg Children\u2019s Center at Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8434-1034","authenticated-orcid":false,"given":"Ravi","family":"Varadhan","sequence":"additional","affiliation":[{"name":"2Quantitative Sciences Division, Department of Oncology, Johns Hopkins University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0253-2177","authenticated-orcid":false,"given":"Christopher J.","family":"Gamper","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Oncology\/Bone Marrow Transplantation, Bloomberg Children\u2019s Center at Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0275-6931","authenticated-orcid":false,"given":"Kenneth R.","family":"Cooke","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Oncology\/Bone Marrow Transplantation, Bloomberg Children\u2019s Center at Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0855-9653","authenticated-orcid":false,"given":"Alexander J.","family":"Ambinder","sequence":"additional","affiliation":[{"name":"3Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8547-9881","authenticated-orcid":false,"given":"Heather J.","family":"Symons","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Oncology\/Bone Marrow Transplantation, Bloomberg Children\u2019s Center at Johns Hopkins Hospital, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8371-9752","authenticated-orcid":false,"given":"Lydia H.","family":"Pecker","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[{"name":"3Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5741-1255","authenticated-orcid":false,"given":"Robert A.","family":"Brodsky","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Department of Medicine, Johns Hopkins University, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8340-1808","authenticated-orcid":false,"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[{"name":"3Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"2026041408014172600_bib1","unstructured":"CDC\n          . Data and Statistics on Sickle Cell Disease. Sickle Cell Disease (SCD). 2024. Accessed 7 April 2025. https:\/\/www.cdc.gov\/sickle-cell\/data\/index.html."},{"issue":"6","key":"2026041408014172600_bib2","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/01.md.0000189089.45003.52","article-title":"Outcome of sickle cell anemia: a 4-decade observational study of 1056 patients","volume":"84","author":"Powars","year":"2005","journal-title":"Medicine (Baltimore)"},{"issue":"17","key":"2026041408014172600_bib3","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2026041408014172600_bib4","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2018-10-880575","article-title":"Decreased median survival of adults with sickle cell disease after adjusting for left truncation bias: a pooled analysis","volume":"133","author":"DeBaun","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2026041408014172600_bib5","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979-2005","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep 1974"},{"issue":"18","key":"2026041408014172600_bib6","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1182\/bloodadvances.2021004394C","article-title":"American Society of Hematology 2021 guidelines for sickle cell disease: stem cell transplantation","volume":"5","author":"Kanter","year":"2021","journal-title":"Blood Adv"},{"issue":"24","key":"2026041408014172600_bib7","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease","volume":"361","author":"Hsieh","year":"2009","journal-title":"N Engl J Med"},{"issue":"4","key":"2026041408014172600_bib8","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. Registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"2026041408014172600_bib9","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbmt.2015.09.012","article-title":"On modeling human leukocyte antigen-identical sibling match probability for allogeneic hematopoietic cell transplantation: estimating the need for an unrelated donor source","volume":"22","author":"Besse","year":"2016","journal-title":"Biol Blood Marrow Transpl"},{"issue":"11","key":"2026041408014172600_bib10","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3390\/jcm8111997","article-title":"Choice of donor source and conditioning regimen for hematopoietic stem cell transplantation in sickle cell disease","volume":"8","author":"Limerick","year":"2019","journal-title":"J Clin Med"},{"issue":"22","key":"2026041408014172600_bib11","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease","volume":"120","author":"Bola\u00f1os-Meade","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2026041408014172600_bib12","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","article-title":"Effect of increased dose of total body irradiation on graft failure associated with HLA-haploidentical transplantation in patients with severe haemoglobinopathies: a prospective clinical trial","volume":"6","author":"Bola\u00f1os-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"6","key":"2026041408014172600_bib13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transpl"},{"issue":"10","key":"2026041408014172600_bib14","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transpl"},{"issue":"6","key":"2026041408014172600_bib15","first-page":"825","article-title":"1994 Consensus Conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2026041408014172600_bib16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2016-07-686642","article-title":"Classification systems for chronic graft-versus-host disease","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"key":"2026041408014172600_bib17","unstructured":"National Cancer Institute\n          . Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Accessed 3 January 2025. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"key":"2026041408014172600_bib18","unstructured":"Gray\n              B\n            \n          . cmprsk: Subdistribution Analysis of Competing Risks. 2024. Accessed 6 February 2025. https:\/\/cran.r-project.org\/web\/packages\/cmprsk\/index.html."},{"issue":"282","key":"2026041408014172600_bib19","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"8","key":"2026041408014172600_bib20","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"9102","key":"2026041408014172600_bib21","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S0140-6736(05)78555-X","article-title":"Transfer of diabetes type 1 by bone-marrow transplantation","volume":"351","author":"Lampeter","year":"1998","journal-title":"The Lancet"},{"issue":"10","key":"2026041408014172600_bib22","first-page":"638","article-title":"Harvest quality, nucleated cell dose and clinical outcomes in bone marrow transplantation: a retrospective study","volume":"29","author":"Mamo","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2026041408014172600_bib23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France","volume":"105","author":"Bernaudin","year":"2020","journal-title":"Haematologica"},{"issue":"9","key":"2026041408014172600_bib24","doi-asserted-by":"crossref","first-page":"e660","DOI":"10.1016\/S2352-3026(22)00206-X","article-title":"Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial","volume":"9","author":"DeZern","year":"2022","journal-title":"Lancet Haematol"},{"issue":"11","key":"2026041408014172600_bib25","doi-asserted-by":"crossref","first-page":"e585","DOI":"10.1016\/S2352-3026(19)30154-1","article-title":"Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study","volume":"6","author":"Eapen","year":"2019","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026041408014172600_bib26","first-page":"30","article-title":"Effect of ABO mismatch and red blood cell alloimmunization on the outcome of hematopoietic cell transplantation for sickle cell disease","volume":"31","author":"Saib","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"12","key":"2026041408014172600_bib27","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.3324\/haematol.2019.216788","article-title":"Risk factors and outcomes according to age at transplantation with an HLA-identical sibling for sickle cell disease","volume":"104","author":"Cappelli","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"2026041408014172600_bib28","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.bbmt.2017.08.038","article-title":"Relationship between mixed donor-recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease","volume":"23","author":"Abraham","year":"2017","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"2026041408014172600_bib29","article-title":"Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia","volume":"7","author":"Mc","year":"2001","journal-title":"Biol Blood Marrow Transpl J Am Soc Blood Marrow Transpl"},{"issue":"17","key":"2026041408014172600_bib30","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2026041408014172600_bib31","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3324\/haematol.2010.031013","article-title":"Quantitatively different red cell\/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease","volume":"96","author":"Andreani","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"2026041408014172600_bib32","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"issue":"23","key":"2026041408014172600_bib33","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1182\/blood.2022017960","article-title":"Increased incidence of hematologic malignancies in SCD after HCT in adults with graft failure and mixed chimerism","volume":"140","author":"Lawal","year":"2022","journal-title":"Blood"},{"key":"2026041408014172600_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4137\/CMO.S8810","article-title":"Development of myelodysplastic syndrome and acute myeloid leukemia 15 years after hydroxyurea use in a patient with sickle cell anemia","volume":"6","author":"Baz","year":"2012","journal-title":"Clin Med Insights Oncol"},{"issue":"7","key":"2026041408014172600_bib35","doi-asserted-by":"crossref","first-page":"E131","DOI":"10.1002\/ajh.24010","article-title":"Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia","volume":"90","author":"Aumont","year":"2015","journal-title":"Am J Hematol"},{"issue":"10","key":"2026041408014172600_bib36","doi-asserted-by":"crossref","first-page":"722","DOI":"10.7326\/0003-4819-155-10-201111150-00024","article-title":"Therapy-related acute myelogenous leukemia in a hydroxyurea-treated patient with sickle cell anemia","volume":"155","author":"Taylor","year":"2011","journal-title":"Ann Intern Med"},{"issue":"2","key":"2026041408014172600_bib37","first-page":"100","article-title":"Barriers to bone marrow transplantation for sickle cell anemia","volume":"2","author":"Walters","year":"1996","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2026041408014172600_bib38","first-page":"47","article-title":"Long-term organ function after HCT for SCD: a report from the Sickle Cell Transplant Advocacy and Research Alliance","volume":"29","author":"Stenger","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2026041408014172600_bib39","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ymthe.2024.01.015","article-title":"A new frontier: FDA approvals for gene therapy in sickle cell disease","volume":"32","author":"Leonard","year":"2024","journal-title":"Mol Ther"},{"key":"2026041408014172600_bib40","volume-title":"FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease","year":"2024"},{"issue":"3","key":"2026041408014172600_bib41","doi-asserted-by":"crossref","first-page":"EVIDoa2400192","DOI":"10.1056\/EVIDoa2400192","article-title":"Haploidentical bone marrow transplantation for sickle cell disease","volume":"4","author":"Kassim","year":"2025","journal-title":"NEJM Evid"},{"issue":"25","key":"2026041408014172600_bib42","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1182\/blood.2023023301","article-title":"An international learning collaborative phase 2 trial for haploidentical bone marrow transplant in sickle cell disease","volume":"143","author":"Kassim","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026041408014172600_bib43","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bbmt.2018.11.027","article-title":"Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative","volume":"25","author":"de la Fuente","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"suppl 1","key":"2026041408014172600_bib44","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1182\/blood-2021-147133","article-title":"Early immune reconstitution after hematopoietic stem cell transplantation for adolescents and adults with sickle cell disease","volume":"138","author":"Vasseur","year":"2021","journal-title":"Blood"},{"issue":"8","key":"2026041408014172600_bib45","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/sj.bmt.1705622","article-title":"A survey on patient perception of reduced-intensity transplantation in adults with sickle cell disease","volume":"39","author":"Chakrabarti","year":"2007","journal-title":"Bone Marrow Transpl"},{"key":"2026041408014172600_bib46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-1-4939-7299-9_4","volume-title":"Gene and Cell Therapies for Beta-Globinopathies","author":"Bernaudin","year":"2017"},{"issue":"1","key":"2026041408014172600_bib47","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1007\/s12185-016-1998-y","article-title":"Assessment of the ovarian reserve with anti-M\u00fcllerian hormone in women who underwent allogeneic hematopoietic stem cell transplantation using reduced-intensity conditioning regimens or myeloablative regimens with ovarian shielding","volume":"104","author":"Nakano","year":"2016","journal-title":"Int J Hematol"},{"issue":"12","key":"2026041408014172600_bib48","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/bmt.2008.416","article-title":"Successful pregnancy and childbirth after reduced-intensity conditioning and partially HLA-mismatched BMT","volume":"43","author":"Fuchs","year":"2009","journal-title":"Bone Marrow Transpl"},{"issue":"6","key":"2026041408014172600_bib49","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ajh.27295","article-title":"Favorable outcome of non-myeloablative allogeneic transplantation in adult patients with severe sickle cell disease: a single center experience of 200 patients","volume":"99","author":"Damlaj","year":"2024","journal-title":"Am J Hematol"},{"issue":"5","key":"2026041408014172600_bib50","first-page":"534","article-title":"Fertility potential and gonadal function in survivors of reduced-intensity hematopoietic stem cell transplantation","volume":"30","author":"Rotz","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"2","key":"2026041408014172600_bib51","doi-asserted-by":"crossref","first-page":"e0213024","DOI":"10.1371\/journal.pone.0213024","article-title":"Ovarian reserve in women with sickle cell disease","volume":"14","author":"Kopeika","year":"2019","journal-title":"PLoS ONE"},{"issue":"25","key":"2026041408014172600_bib52","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"2026041408014172600_bib53","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.15169","article-title":"Pain and opioid use after reversal of sickle cell disease following HLA-matched sibling haematopoietic stem cell transplant","volume":"184","author":"Darbari","year":"2019","journal-title":"Br J Haematol"},{"issue":"12","key":"2026041408014172600_bib54","first-page":"1018","article-title":"Low rates of cerebral infarction after hematopoietic stem cell transplantation in patients with sickle cell disease at high risk for stroke","volume":"27","author":"Carpenter","year":"2021","journal-title":"Transpl Cell Ther"},{"issue":"4","key":"2026041408014172600_bib55","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/bloodadvances.2024013693","article-title":"Is allogeneic transplantation for sickle cell disease still relevant in the era of gene therapy?","volume":"9","author":"Jones","year":"2025","journal-title":"Blood Adv"},{"issue":"6","key":"2026041408014172600_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamapediatrics.2020.7140","article-title":"A budget impact analysis of gene therapy for sickle cell disease","volume":"175","author":"DeMartino","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"7","key":"2026041408014172600_bib57","first-page":"366","article-title":"The cost of hematopoietic stem-cell transplantation in the United States","volume":"10","author":"Broder","year":"2017","journal-title":"Am Health Drug Benefits"},{"issue":"8","key":"2026041408014172600_bib58","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1093\/pm\/pnaa464","article-title":"Pain experiences of adults with sickle cell disease and hematopoietic stem cell transplantation: a qualitative study","volume":"22","author":"Abu Al Hamayel","year":"2021","journal-title":"Pain Med"},{"issue":"4","key":"2026041408014172600_bib59","first-page":"283","article-title":"Physical, mental, and social health of adult patients with sickle cell disease after allogeneic hematopoietic stem cell transplantation: a mixed-methods study","volume":"29","author":"Dovern","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"12","key":"2026041408014172600_bib60","doi-asserted-by":"crossref","first-page":"e946","DOI":"10.1016\/S2352-3026(23)00306-X","article-title":"Life after sickle cell disease, is it really uhuru?","volume":"10","author":"Pecker","year":"2023","journal-title":"Lancet Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2202\/2510910\/blooda_adv-2025-017413-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/7\/2202\/2510910\/blooda_adv-2025-017413-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:01:54Z","timestamp":1776168114000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/7\/2202\/566203\/Bone-marrow-transplantation-for-sickle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,4,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017413","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,14]]},"published":{"date-parts":[[2026,3,26]]}}}